CERo Therapeutics
Hongxiu Ning has held various scientific roles at companies such as CERo Therapeutics, Allogene Therapeutics, Pfizer, and University of California, San Francisco. Currently working at UCSF Medical Center, with a background in oncology and cancer biology, Hongxiu's research focuses on activating endogenous stem cells using non-invasive methods and exploring related mechanisms. Prior to this, Hongxiu was involved in mesenchymal stem cell research during postdoctoral training at UCSF.
This person is not in any teams
CERo Therapeutics
CERo Therapeutics, Inc. is a new cellular immunotherapy company. We have created a hybrid platform that integrates innate and adaptive programs to eliminate disease.